Assessment of Prognostic Factors in Epithelial Ovarian Cancer

Basit Öğe Kaydı
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405
dc.authoridHacioglu, Bekir/0000-0001-8490-3239
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.authorwosidHacioglu, Bekir/GZH-1824-2022
dc.contributor.authorOnal, Yilmaz
dc.contributor.authorKostek, Osman
dc.contributor.authorHacioglu, Muhammet Bekir
dc.contributor.authorErdogan, Bulent
dc.contributor.authorKodaz, Hilmi
dc.contributor.authorBekmez, Esma Turkmen
dc.contributor.authorHacibekiroglu, Ilhan
dc.date.accessioned2024-06-12T10:56:14Z
dc.date.available2024-06-12T10:56:14Z
dc.date.issued2017
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjectives: Ovarian cancer is the second most common gynecological cancer, and has a 5-year survival rate of about 40% to 45%. This ratio ranges from 15% to 95%, based on prognostic factors. There are numerous clinical, pathological and biological factors related to prognosis. The aim of this study was to assess prognostic factors in advanced epithelial ovarian cancer. Methods: A total of 119 stage III and stage IV ovarian cancer patients were evaluated. The patients age, menopausal status, age of menarche, number of children, height and weight values, surgery, tumor histopathological features, presence of metastasis, residual tumor volume, presence of ascites, abdominal lavage cytology, chemotherapy regimen, number of chemotherapy cycles, the first and last chemotherapy dates, relapse, and recent status were evaluated. Results: The median age of the study patients was 54 years (minimum: 34, maximum: 79 years). The pathological stages were 10 (8.6%) patients with IIIA, 6 (5%) patients with IIIB, 76 (63.9%) patients with IIIC, and 27 (22.7%) patients with stage IV. In multivariate analysis, age of diagnosis (hazard ratio [HR]: 0.44; 95% confidence interval [CI], 0.22-087; p=0.01), postoperative tumor residual status (HR: 0.32; 95% CI, 0.14-0.71; p<0.01), number of adjuvant chemotherapies (HR: 0.48; 95% CI, 0.23-0.98; p=0.04), and platinum sensitivity (HR: 0.37; 95% CI, 0.18-0.74; p<0.01) were found to be independent variables related to longer survival. Notably, a patient treated with more than 6 cycles of chemotherapy had a worse prognosis. Conclusion: Independent indicators of a poor prognosis in our study were determined to be advanced age at diagnosis, a residual tumor more than 2 cm in size, more than 6 cycles of chemotherapy, and the presence of platinum-resistant disease. A multidisciplinary approach is needed to improve prognosis.en_US
dc.identifier.doi10.14744/ejmo.2017.43531
dc.identifier.endpage+en_US
dc.identifier.issn2587-196X
dc.identifier.issue2en_US
dc.identifier.startpage61en_US
dc.identifier.urihttps://doi.org/10.14744/ejmo.2017.43531
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19711
dc.identifier.volume1en_US
dc.identifier.wosWOS:000604201700002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofEurasian Journal Of Medicine And Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChemotherapyen_US
dc.subjectMortalityen_US
dc.subjectOvarian Canceren_US
dc.subjectPrognosisen_US
dc.subjectResidual Tumoren_US
dc.subjectStage-Iiien_US
dc.subjectPhase-Iiien_US
dc.subjectFollow-Upen_US
dc.subjectSurvivalen_US
dc.subjectSurgeryen_US
dc.subjectRisken_US
dc.subjectCarcinomaen_US
dc.subjectTherapyen_US
dc.subjectAscitesen_US
dc.subjectCyclophosphamideen_US
dc.titleAssessment of Prognostic Factors in Epithelial Ovarian Canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu